BioSpace News Archive

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter ended December 31, 2023 and provided an overview of its recent operational highlights.

Xtant Medical Holdings, Inc. reported financial and operating results for the fourth quarter and year ended December 31, 2023.

Turbine and Harmonic Discovery have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine’s Simulated Cell™ platform.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2023.

Lutris Pharma announced the appointment Moshe “Mori” Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.

Ionis Pharmaceuticals, Inc. announced that management will participate in fireside chats at the following investor conferences.

Quince Therapeutics, Inc. today provided an update on the company’s development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Glaukos Corporation announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA.

VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).

Context Therapeutics Inc. Today announced that on March 28, 2024, the Company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a first-in-human clinical study of CTIM-76.